Get the Stockscreener App
14.96
2.40%
0.35
After Hours:
14.58
-0.38
-2.54%
Promis Neurosciences Inc stock is traded at $14.96, with a volume of 24,849.
It is up +2.40% in the last 24 hours and up +82.22% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$14.61
Open:
$14.44
24h Volume:
24,849
Relative Volume:
0.16
Market Cap:
$32.20M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-74.95
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
+14.20%
1M Performance:
+82.22%
6M Performance:
-14.51%
1Y Performance:
-34.40%
1-Day Range:
$14.32
$15.05
1-Week Range:
$12.70
$15.05
52-Week Range:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
14.96 | 31.45M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Promis Neurosciences Inc Stock (PMN) Latest News
SPHERA FUNDS MANAGEMENT LTD. Acquires Additional Shares in ProMIS Neurosciences Inc. - GuruFocus
ProMIS Neurosciences: Phase 1b Alzheimer's trial fully enrolled and financed, with pivotal data expected in 2026 - TradingView
Published on: 2026-02-10 02:21:08 - baoquankhu1.vn
Guggenheim Remains a Buy on ProMIS Neurosciences (PMN) - The Globe and Mail
Insider Stock Purchases: February 06, 2026 - Quiver Quantitative
ProMIS Neurosciences (PMN) Rating Maintained but Price Target Sl - GuruFocus
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Profit Review: Can ProMIS Neurosciences Inc. continue delivering strong returnsJuly 2025 Trade Ideas & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Promis Neurosciences (NASDAQ:PMN) Short Interest Down 14.8% in January - Defense World
ProMIS Neurosciences Announces $75 Million PIPE Financing - The Globe and Mail
ProMIS Neurosciences raises $175 million in PIPE financing By Investing.com - Investing.com South Africa
ProMIS Neurosciences Inc. (PMN) stock: surges 34% after $175M PIPE financing deal - parameter.io
ProMIS Neurosciences Secures $175 Mln In Private Financing - Nasdaq
ProMIS Neurosciences Stock Fluctuates Amid Market Developments - timothysykes.com
ProMIS Neurosciences Signs Multiple Material Agreements - TradingView
ProMIS Neurosciences raises $175 million in PIPE financing - Investing.com
ProMIS Neurosciences stock soars after $175 million private placement By Investing.com - Investing.com South Africa
ProMIS Neurosciences Secures $175 Million in PIPE Financing to Extend Cash Runway and Support Alzheimer’s Disease Clinical Study - Quiver Quantitative
ProMIS Neurosciences stock soars after $175 million private placement - Investing.com
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - The Manila Times
ProMIS lines up up to $175M to extend runway into 2028, fund Alzheimer’s trial - stocktitan.net
RSI Check: What hedge funds are buying Akoya Biosciences IncQuarterly Trade Summary & Free Reliable Trade Execution Plans - baoquankhu1.vn
ProMIS Neurosciences, Inc. announced that it expects to receive $75.464029 million in funding from a group of investors - marketscreener.com
Aug Breakouts: Whats next for ProMIS Neurosciences Inc stockEarnings Beat & Scalable Portfolio Growth Ideas - baoquankhu1.vn
How cyclical is ProMIS Neurosciences Inc.’s revenue streamMarket Activity Recap & Daily Profit Maximizing Trade Tips - bollywoodhelpline.com
Promis Neurosciences (NASDAQ:PMN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Quarterly Earnings: Is ProMIS Neurosciences Inc benefiting from innovation trends2025 Historical Comparison & Expert Curated Trade Setups - baoquankhu1.vn
Aug Breakouts: Can ProMIS Neurosciences Inc continue delivering strong returnsBond Market & AI Optimized Trade Strategies - baoquankhu1.vn
Bull Run: What are analysts price targets for DMAAMarket Growth Report & Real-Time Market Sentiment Reports - baoquankhu1.vn
Gap Down: Can ProMIS Neurosciences Inc continue delivering strong returnsPortfolio Profit Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Bull Bear: Whats ProMIS Neurosciences Incs historical returnTreasury Yields & Short-Term Trading Alerts - baoquankhu1.vn
ProMIS Neurosciences regains Nasdaq compliance - MSN
US Market Wrap: Is FTAIN exposed to political riskJuly 2025 Gainers & Target Return Focused Stock Picks - baoquankhu1.vn
Gains Report: Does ProMIS Neurosciences Inc outperform in volatile marketsQuarterly Trade Review & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
What is the cash position of ProMIS Neurosciences Inc2025 Volatility Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Market Moves: Can ProMIS Neurosciences Inc continue delivering strong returnsMarket Growth Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Institution Moves: What is ProMIS Neurosciences Incs P E ratio telling usEarnings Overview Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
US Market Recap: Can ProMIS Neurosciences Inc continue delivering strong returnsJuly 2025 Volume & High Win Rate Trade Tips - baoquankhu1.vn
Why ProMIS Neurosciences Inc. stock appeals to analystsJuly 2025 Action & Weekly Market Pulse Alerts - Улправда
Is ProMIS Neurosciences Inc. (23J0) stock considered safe havenBreathability and Upper Notes & HOKA model picks for your routine - ulpravda.ru
Can ProMIS Neurosciences Inc. stock beat analyst upgradesWeekly Trend Report & Community Consensus Trade Signals - Улправда
How dovish Fed policy supports ProMIS Neurosciences Inc. (23J0) stockPortfolio Return Report & Reliable Intraday Trade Plans - Улправда
Setup Watch: How dovish Fed policy supports ProMIS Neurosciences Inc 23J0 stockJuly 2025 Market Mood & Smart Swing Trading Alerts - moha.gov.vn
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial - MSN
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Guidance Update: Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansionWeekly Profit Summary & Community Consensus Trade Signals - Улправда
Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansion2025 Volatility Report & Daily Entry Point Trade Alerts - Улправда
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):